OSTEOMICS: Identifying Regulators of Bone Homeostasis

Launched by RELATION THERAPEUTICS · Feb 8, 2023

Keywords

ClinConnect Summary

The OSTEOMICS trial is studying how different factors affect bone health, particularly in people with conditions like osteoporosis and osteoarthritis. These bone diseases can make bones weaker and joints less healthy, especially as we age. The researchers want to learn more about how our bones work at the cellular level and how things like genetics, diet, and lifestyle can influence bone quality. To do this, they will collect bone samples from patients undergoing orthopedic surgeries, including joint replacements and fracture repairs. By analyzing these samples, they hope to identify new ways to prevent and treat bone diseases.

To participate in the trial, you should be between 18 and 110 years old and be undergoing certain types of orthopedic surgeries, such as total joint replacements or surgeries for fractures. While the study is open to a wide range of patients to get a broad understanding of bone health, those who cannot provide consent or have certain serious health conditions will not be eligible. Participants can expect to contribute to important research that may lead to better treatments for bone diseases in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with osteoarthritis undergoing total joint arthroplasty, osteotomy or arthrodesis of any joint (including hip, knee, shoulder, wrist, elbow, ankle).
• • 2. Patient with fractured neck of femurs undergoing hemiarthroplasty or total hip arthroplasty, or other internal fixation procedure.
• • 3. Patients undergoing acute low-velocity or fragility fracture fixation surgery.
• • 4. Patients aged between 18-110 years old with capacity to consent.
• • Since deteriorating bone health including diseases like osteoporosis are primarily conditions of older age there is no practical upper age-limit. However, study involvement is limited by suitability for surgery which encompasses multiple factors considered on an individual case basis including age, frailty, comorbidities, baseline mobility, renal function and ability to consent (for instance due to dementia or delirium).
• • We note that our inclusion criteria is purposefully broad as we aim to deduce trends across a wide range of conditions and backgrounds.
• Exclusion Criteria:
• • 1. Patients unable to provide informed consent.
• • 2. Patients with suspected/established underlying malignancy.
• • 3. Patients with suspected/established osteomyelitis.
• • 4. Patients with suspected/established bloodborne disease
• • 5. Patients who are currently a subject of a clinical trial involving an investigational medicinal product.